keyboard_arrow_up

Investigation Report on China Telmisartan Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Telmisartan Market, 2009-2018. According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack.
Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Telmisartan was firstly developed by Boehringer Ingelheim and approved to the U.S. market for the first time in 1999 with the trade name "Micardis". It is a once-daily oral medication for the treatment of essential hypertension. In the same year, telmisartan was jointly sold as "Micardis" by Boehringer Ingelheim and "Pritor" by Glaxo Wellcome in Germany. It was approved to market in December 1999 in Philippines. In 2000, it was approved to market in Australia, Belgium and Britain. Glaxo Wellcome owns the marketing right worldwide except in Japan and the U.S. The company is also developing compound preparation of telmisartan and other hypertension drugs. Abbott Laboratories holds the sales license of this product in the United States. At the end of 2000, Boehringer Ingelheim introduced raw material and preparation of telmisartan into Chinese market. Several telmisartan generic drugs have also been approved to Chinese market in succession since 2004.
Statistics shows that incidence of hypertension among Chinese people aged 15 and above is 24%. There are more than 260 million hypertension patients in the country, with at least one hypertension patient among 5 adults. The prevention and cure for hypertension in China is faced with very tough challenges. Less than 40% of hypertension patients are aware of their illness, while only one-fourth of them are under proper management. Among those who are under management, 60% are willing to take medicines, while only 50% of them have their blood pressure under control. According to Investigation, more than CNY 40 billion is annually spent on hypertension treatment in China. In 2013, market size of antihypertensive prescription drug in China exceeded CNY 20 billion, increased more than 15% YOY. This has shown great potential of Chinese market.
The CAGR of sales value of telmisartan surpassed 65% in Chinese sample hospitals from 2005 to 2010. Its growth rate dropped slightly in 2011, but an annual growth rate of 10% is still maintained. From the perspective of sales revenue, original drug produced by Boehringer Ingelheim has seized most of Chinese telmisartan market while other market share is occupied by generic drugs produced by manufacturers such as Yichang Changjiang Pharmaceutical Co., Ltd. and Beijing Double-Crane Pharmaceutical Co., Ltd. It is estimated that incidence of hypertension in China will continue to rise year by year due to improvement of living standard, changes of eating habit, increasing stress of life and lack of health awareness. As Chinese people's incomes increase, the affordability of antihypertension drugs increases. Estimation shows that market size of telmisartan in China will keep rising in the next few years.

Through this report, the readers can acquire the following information:
-Market Share of Telmisartan Produced by Different Manufacturers in China Hospital Market
-Sales price of Telmisartan in China Hospital Market
-Major Telmisartan Manufacturers in China
-Share of Telmisartan in Different Dosage Forms in China Hospital Market
-Prospect of China Telmisartan Market

The following enterprises and people are recommended to purchase this report:
-Antihypertensive APIs and Finished Product Manufacturers
-Medical Institutions

To view the table of contents and know more details please visit Investigation Report on China Telmisartan Market, 2009-2018.